載入...
免疫检查点抑制剂治疗EGFR突变非小细胞肺癌的研究进展
In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...
Na minha lista:
| 發表在: | Zhongguo Fei Ai Za Zhi |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
中国肺癌杂志编辑部
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6105349/ https://ncbi.nlm.nih.gov/pubmed/30172273 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|